[1] Eichenfield LF,Beck L.Elidel (pimecrolimus) cream 1%;a nonsteroidal topical agent for the treatment of atopic dermatitis.J Allergy Clin Immunol,2003,111;1153-1168.
[2] Billich A,Aschauer H,Aszodi A,et al.Percutaneous absorption of drugs used in atopic eczema;pimecrolimus permeates less through skin than corticosteroids and tacrolimus.Int J Pharm,2004,269;29-35.
[3] Meingassner JG,Aschauer H,Stuetz A,et al.Pimecrolimus permeates less than tacrolimus through normal,inflamed,or corticosteroid-pretreated skin.Exp Dermatol,2005,14;752-757.
[4] Van Leent EJ,Ebelin ME,Burtin P,et al.Low systemic exposure after repeated topical application of Pimecrolimus (Elidel,SDZ ASM 981) in patients with atopic dermatitis.Dermatology,2002,204;63-68.
[5] Allen BR,Lakhanpaul M,Morris A,et al.Systemic exposure,tolerability,and efficacy of pimecrolimus cream 1% in atopic dermatitis patients.Arch Dis Child,2003,88;969-973.
[6] Staab D,Pariser D,Gottlieb AB,et al.Low systemic absorption and good tolerability of pimecrolimus,administered as 1% cream (Elidel) in infants with atopic dermatitis-a multicenter,3-week,open-label study.Pediatr Dermatol,2005,22;465-471.
[7] Paul C,Cork M,Rossi AB,et al.Safety and tolerability of 1% pimecrolimus cream among infants;experience with 1 133 patients treated for up to 2 years.Pediatrics,2006,117;e 118-128.
[8] Harper J,Green A,Scott G,et al.First experience of topical SDZ ASM 981 in children with atopic dermatitis.Br J Dermatol,2001,144;781-787.
[9] Eichenfield LF,Lucky AW,Boguniewicz M,et al.Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.J Am Acad Dermatol,2002,46;495-504.
[10] Ho VC,Gupta A,Kaufmann R,et al.Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.J Pediatr,2003,142;155-162.
[11] Luger T,Van Leent EJ,Graeber M,et al.SDZ ASM 981;an emerging safe and effective treatment for atopic dermatitis.Br J Dermatol,2001,144;788-794.
[12] Luger T,Lahfa M,Folster-Holst R,et al.Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.J Dermatol Treat,2004,15;169-178.
[13] Kapp A,Papp K,Bingham A,et al.Long-term management of atopic dermatitis in infants with topical pimecrolimus,a nonsteroid anti-inflammatory drug.J Allergy Clin Immunol,2002,110;277-284.
[14] Wahn U,Bos JD,Goodfield M,et al.Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.Pediatrics,2002,110;e2.
[15] Meurer M,Folster-Holst R,Wozel G,et al.Pimecrolimus cream in the long-term management of atopic dermatitis in adults;a six-month study.Dermatology,2002,205;271-277.
[16] Meurer M,Fartasch M,Albrecht G,et al.CASM-DE-01 Study Group.Long-term efficacy and safety of pimecrolimus cream 1%in adults with moderate atopic dermatitis.Dermatology,2004,208;365-372.
[17] Siegfried EC,Koman N,Abrams K.Long-term management with pimecrolimus cream 1% for atopic dermatitis reduces flare frequency and corticosteroid use.J Am Acad Dermatol,2004,50;9.
[18] Graham-Brown RA,Grassberger M.Pimecrolimus;a review of pre-clinical and clinical data.Int J Clin Pract,2003,57;319-327.
[19] Papp KA,Werfel T,Folster-Holst R,et al.Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children;a two-year stuudy.J Am Acad Dermatol,2005,52;240-246.
[20] Queille-Roussel C,Paul C,Duteil L,et al.The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks;a randomized,double-blind controlled study.Br J Dermatol,2001,144;507-513.
[21] Papp KA,Breuer K,Meurer M,et al.Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination.J Am Acad Dermatol,2005,52;247-253.
[22] Rappersberger K,Komar M,Ebelin ME,et al.Pimecrolimus identifies a common genomic anti-inflammatory profile,is clinically highly effective in psoriasis and is well tolerated.J Invest Dermatol,2002,119;876-877.
[23] Fonacier L,Spergel J,Charlesworth EN,et al.Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy,Asthma and Immunology and the American Academy of Allergy,Asthma and Immunology.J Allergy Clin Immunol,2005,115;1249-1253. |
